IRON-DEFICIENCY ANEMIAS WORSEN SOME CARDIOVASCULAR DISEASES: THE ROLE OF INTRAVENOUS FERRIC CARBOXYMALTOSE
Main Article Content
Keywords
ferric carboxymaltose (FCM), iron deficiency, anemia, cardiovascular outcomes, hospitalization, quality of life
Abstract
Introduction: Iron-deficiency anemias exacerbate cardiovascular diseases, necessitating effective interventions. This study explores the role of intravenous Ferric Carboxymaltose (FCM) in mitigating cardiovascular complications associated with iron deficiency.
Objective: Investigate the impact of FCM on cardiovascular outcomes, including hospitalizations, mortality, and quality of life, in comparison to a placebo group.
Methodology: This retrospective analysis investigated the effect of intravenous FCM on cardiovascular outcomes in 70 adults with heart failure and iron deficiency. Data was collected from randomized, placebo-controlled trials with a follow-up of 52 weeks. The primary endpoints were the impact of FCM on total cardiovascular hospitalizations and death, and total heart failure hospitalizations and death. Secondary endpoints included total cardiovascular and heart failure hospitalizations, and time to cardiovascular death. Safety assessment included monitoring for treatment-emergent adverse events. Statistical analysis employed frequency, mean, percentage, negative binomial and Cox models, and Pearson correlation coefficients
Results: FCM exhibited significant efficacy, reducing total cardiovascular hospitalizations and mortality (p=0.003), total heart failure hospitalizations and mortality (p=0.002), total cardiovascular hospitalizations (p=0.001), and total heart failure hospitalizations (p=0.001). While FCM demonstrated positive improvements in hemoglobin levels, NYHA class, health-related quality of life, and exercise capacity, it showed varied effects on gastrointestinal adverse events. Pearson correlation coefficients unveiled associations between participant characteristics.
Conclusion: Intravenous FCM showcased a substantial reduction in cardiovascular events and enhanced various health indicators compared to a placebo. These findings underscore FCM's potential in ameliorating cardiovascular risks associated with iron deficiency.
References
2. Lakhal-Littleton S. Iron deficiency as a therapeutic target in cardiovascular disease. Pharmaceuticals. 2019 Aug 28;12(3):125.
3. Marques O, Weiss G, Muckenthaler MU. The role of iron in chronic inflammatory diseases: From mechanisms to treatment options in anemia of inflammation. Blood, The Journal of the American Society of Hematology. 2022 Nov 10;140(19):2011-23.
4. Clark SF. Iron deficiency anemia. Nutrition in clinical practice. 2008 Apr;23(2):128-41.
5. Camaschella C. New insights into iron deficiency and iron deficiency anemia. Blood reviews. 2017 Jul 1;31(4):225-33.
6. Koning NJ, Simon LE, Asfar P, Baufreton C, Boer C. Systemic microvascular shunting through hyperdynamic capillaries after acute physiological disturbances following cardiopulmonary bypass. American Journal of Physiology-Heart and Circulatory Physiology. 2014 Oct 1;307 (7):H967-75.
7. Santini F, Onorati F, Telesca M, Patelli F, Berton G, Franchi G, Faggian G, Mazzucco A. Pulsatile pulmonary perfusion with oxygenated blood ameliorates pulmonary hemodynamic and respiratory indices in low-risk coronary artery bypass patients. European journal of cardio-thoracic surgery. 2011 Oct 1;40(4):794-803.
8. Lieu PT, Heiskala M, Peterson PA, Yang Y. The roles of iron in health and disease. Molecular aspects of medicine. 2001 Feb 1;22(1-2):1-87.
9. Jankowska EA, von Haehling S, Anker SD, Macdougall IC, Ponikowski P. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. European heart journal. 2013 Mar 14;34(11):816-29.
10. Toblli JE, Angerosa M. Optimizing iron delivery in the management of anemia: patient considerations and the role of FCM. Drug design, development and therapy. 2014 Dec 11:2475-91.
11. Ponikowski P, Van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C. Beneficial effects of long-term intravenous iron therapy with FCM in patients with symptomatic heart failure and iron deficiency. European heart journal. 2015 Mar 14;36(11):657-68.
12. Jankowska EA, Kirwan BA, Kosiborod M, Butler J, Anker SD, McDonagh T, Dorobantu M, Drozdz J, Filippatos G, Keren A, Khintibidze I. The effect of intravenous FCM on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. European heart journal. 2021 Aug 14;42(31):3011-20.
13. Correale M, Paolillo S, Mercurio V, Ruocco G, Tocchetti CG, Palazzuoli A. Non-cardiovascular comorbidities in heart failure patients and their impact on prognosis. Kardiologia Polska (Polish Heart Journal). 2021;79(5):493-502.
14. Humphries KH, Izadnegahdar M, Sedlak T, Saw J, Johnston N, Schenck-Gustafsson K, Shah RU, Regitz-Zagrosek V, Grewal J, Vaccarino V, Wei J. Sex differences in cardiovascular disease–impact on care and outcomes. Frontiers in neuroendocrinology. 2017 Jul 1;46:46-70.
15. Garcia M, Mulvagh SL, Bairey Merz CN, Buring JE, Manson JE. Cardiovascular disease in women: clinical perspectives. Circulation research. 2016 Apr 15;118(8):1273-93.
16. Regitz-Zagrosek V, Kararigas G. Mechanistic pathways of sex differences in cardiovascular disease. Physiological reviews. 2017 Jan;97(1):1-37.
17. Lichtenstein GR, Onken JE. Improved hemoglobin response with FCM in patients with gastrointestinal-related iron-deficiency anemia versus oral iron. Digestive Diseases and Sciences. 2018 Nov; 63:3009-19.
18. Motta I, Mantovan G, Consonni D, Brambilla AM, Materia M, Porzio M, Migone De Amicis M, Montano N, Cappellini MD. Treatment with FCM in stable patients with severe iron deficiency anemia in the emergency department. Internal and Emergency Medicine. 2020 Jun; 15:629-34.
19. Joseph J, Claggett BC, Anand IS, Fleg JL, Huynh T, Desai AS, Solomon SD, O’Meara E, Mckinlay S, Pitt B, Pfeffer MA. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC: Heart Failure. 2016 Jun;4(6):477-86.
20. Giudice R, Izzo R, Manzi MV, Pagnano G, Santoro M, Rao MA, Di Renzo G, De Luca N, Trimarco V. Lifestyle-related risk factors, smoking status and cardiovascular disease. High Blood Pressure & Cardiovascular Prevention. 2012 Jun; 19:85-92.
21. Grammer TB, Kleber ME, Silbernagel G, Pilz S, Scharnagl H, Tomaschitz A, König W, März W. Hemoglobin, iron metabolism and angiographic coronary artery disease (The Ludwigshafen Risk and Cardiovascular Health Study). Atherosclerosis. 2014 Oct 1;236(2):292-300.
22. Von Haehling S, Jankowska EA, Van Veldhuisen DJ, Ponikowski P, Anker SD. Iron deficiency and cardiovascular disease. Nature Reviews Cardiology. 2015 Nov;12(11):659-69.
23. Bi Y, Ajoolabady A, Demillard LJ, Yu W, Hilaire ML, Zhang Y, Ren J. Dysregulation of iron metabolism in cardiovascular diseases: From iron deficiency to iron overload. Biochemical Pharmacology. 2021 Aug 1; 190:114661.
24. Loncar G, Obradovic D, Thiele H, von Haehling S, Lainscak M. Iron deficiency in heart failure. ESC heart failure. 2021 Aug;8(4):2368-79.
25. Lakatta EG. Age-associated cardiovascular changes in health: impact on cardiovascular disease in older persons. Heart failure reviews. 2002 Jan; 7:29-49.
26. Bhutia A, Singh SK, Reema N, Hijam D, Belinda N, Sora T. Iron Profile In Heart Failure Patients–A Hospital Based Cross-Sectional Study In North-Eastern Part Of India. Int J Acad Med Pharm. 2024;6(1):200-5.
27. Gentile F, Sciarrone P, Zamora E, De Antonio M, Santiago E, Domingo M, Aimo A, Giannoni A, Passino C, Codina P, Bayes-Genis A. Body mass index and outcomes in ischaemic versus non-ischaemic heart failure across the spectrum of ejection fraction. European journal of preventive cardiology. 2021 Sep 1;28(9):948-55.
28. Sliwa K, Forster O, Tibazarwa K, Libhaber E, Becker A, Yip A, Hilfiker-Kleiner D. Long-term outcome of peripartum cardiomyopathy in a population with high seropositivity for human immunodeficiency virus. International journal of cardiology. 2011 Mar 3;147(2):202-8.
29. Kramer TT, Viethen T, Natsina K, Gerhardt F, Ten-Freyhaus H, Dumitrescu D, Hellmich M, Baldus S, Rosenkranz S. Beneficial Effects of FCM in Patients With Pulmonary Arterial Hypertension and Iron Deficiency: A Long-term Study. Circulation. 2019 Nov 19;140 (Suppl_1): A12081-.
30. Thomas GN, ó Hartaigh B, Bosch JA, Pilz S, Loerbroks A, Kleber ME, Fischer JE, Grammer TB, Böhm BO, März W. Vitamin D levels predict all-cause and cardiovascular disease mortality in subjects with the metabolic syndrome: the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. Diabetes care. 2012 May 1;35(5):1158-64.
31. Pellicori P, Zhang J, Lukaschuk E, Joseph AC, Bourantas CV, Loh H, Bragadeesh T, Clark AL, Cleland JG. Left atrial function measured by cardiac magnetic resonance imaging in patients with heart failure: clinical associations and prognostic value. European heart journal. 2015 Mar 21;36(12):733-42.
32. Del Pinto R, Ferri C. Iron deficiency in heart failure: diagnosis and clinical implications. European Heart Journal Supplements. 2022 Nov 12;24(Supplement_I) :I96-9.
33. Grote Beverborg N, Klip IT, Meijers WC, Voors AA, Vegter EL, van der Wal HH, Swinkels DW, van Pelt J, Mulder AB, Bulstra SK, Vellenga E. Definition of iron deficiency based on the gold standard of bone marrow iron staining in heart failure patients. Circulation: Heart Failure. 2018 Feb;11(2): e004519.
34. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA. FCM in patients with heart failure and iron deficiency. New England Journal of Medicine. 2009 Dec 17;361(25):2436-48.
35. Comín-Colet J, Verdú-Rotellar JM, Vela E, Cleries M, Bustins M, Mendoza L, Badosa N, Cladellas M, Ferré S, Bruguera J. Efficacy of an integrated hospital-primary care program for heart failure: a population-based analysis of 56 742 patients. Revista Española de Cardiología (English Edition). 2014 Apr 1;67(4):283-93.
36. Evstatiev R, Alexeeva O, Bokemeyer B, Chopey I, Felder M, Gudehus M, Iqbal T, Khalif I, Marteau P, Stein J, Gasche C. FCM prevents recurrence of anemia in patients with inflammatory bowel disease. Clinical Gastroenterology and Hepatology. 2013 Mar 1;11(3):269-77.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Hidayatullah
Senior Register Cardiology Peshawar Institute of Cardiology, Peshawar - Pakistan
Zeeshan Ahmed Khattak
Pharmacist Department of Pharmacy, Burjeel Medical City - Abu Dhabi
Anas Ahmad
Pharmacist Department of Pharmacy, Aman Hospital - Qatar
Sobia Junaid
SMO ICU Department Darul Sehat Hospital, Karachi - Pakistan
Maheen Hashmi
Dow University of Health Sciences, Karachi - Pakistan
Amjad Ali
Lecturer, Nursing Department, Bahria University of Health Sciences, Karachi - Pakistan
Syed Danial Naim
Medical Officer, Emergency Department Indus Hospital & Health Network, Karachi - Pakistan
Umair Ul Haq
MBBS Student, Bannu Medical College, Peshawar - Pakistan